Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference CHARLOTTESVILLE, Va., Jan. 11, 2021 — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows: Event: Date: The recorded presentation can be accessed by conference participants and the presentation deck can be accessed on the investor relations section of the Diffusion Pharmaceuticals’ website. About Diffusion Pharmaceuticals Inc. Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, trans sodium crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, our product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. We continue to explore alternatives regarding how best to capitalize upon the value of DFN-529 and our associated intellectual property. For more information, please visit us on the web at www.diffusionpharma.com.